Add to ORKGCharacteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis fro
Late onset neutropenia (LON) related to rituximab or rituximab plus chemotherapy is defined as an un...
Rituximab is a monoclonal antibody directed against the CD20 antigen on normal and neoplastic B-lym...
Biomarkers of clinical response to rituximab (RTX) therapy and early predictors of outcome are still...
International audienceOBJECTIVES:To evaluate the prevalence of late-onset neutropenia and its compli...
Background Recent studies have reported the occurrence of late onset neutropenia (LON) in 3%-27% of ...
Background: Late onset neutropaenia (LON) is a recognised complication of rituximab (RTX) treatment ...
Objective: Unusual or unexpected effect of treatment Background: We describe here 2 patients who dev...
Copyright © 2015 Mariangeĺı Arroyo-Ávila et al.This is an open access article distributed under th...
Mechanisms for late-onset neutropenia (LON) after rituximab treatment are poorly defined both for no...
Monoclonal antibody therapy with the anti-CD20 antibody rituximab has already had an enor-mous impac...
Background: The causes and mechanisms of late-onset neutropenia (LON) following rituximab treatment ...
The monoclonal anti-CD20 antibody Rituximab (RTX) is increasingly used in allogeneic stem cell trans...
Large granular lymphocytic (LGL) leukemia is an uncommon, usually indolent, lymphoproliferative diso...
Acesso restrito: Texto completo. p. 469-475Biomarkers of clinical response to rituximab (RTX) therap...
© 2015 Nasrallah et al.Introduction: In the present study, we sought to identify markers in patients...
Late onset neutropenia (LON) related to rituximab or rituximab plus chemotherapy is defined as an un...
Rituximab is a monoclonal antibody directed against the CD20 antigen on normal and neoplastic B-lym...
Biomarkers of clinical response to rituximab (RTX) therapy and early predictors of outcome are still...
International audienceOBJECTIVES:To evaluate the prevalence of late-onset neutropenia and its compli...
Background Recent studies have reported the occurrence of late onset neutropenia (LON) in 3%-27% of ...
Background: Late onset neutropaenia (LON) is a recognised complication of rituximab (RTX) treatment ...
Objective: Unusual or unexpected effect of treatment Background: We describe here 2 patients who dev...
Copyright © 2015 Mariangeĺı Arroyo-Ávila et al.This is an open access article distributed under th...
Mechanisms for late-onset neutropenia (LON) after rituximab treatment are poorly defined both for no...
Monoclonal antibody therapy with the anti-CD20 antibody rituximab has already had an enor-mous impac...
Background: The causes and mechanisms of late-onset neutropenia (LON) following rituximab treatment ...
The monoclonal anti-CD20 antibody Rituximab (RTX) is increasingly used in allogeneic stem cell trans...
Large granular lymphocytic (LGL) leukemia is an uncommon, usually indolent, lymphoproliferative diso...
Acesso restrito: Texto completo. p. 469-475Biomarkers of clinical response to rituximab (RTX) therap...
© 2015 Nasrallah et al.Introduction: In the present study, we sought to identify markers in patients...
Late onset neutropenia (LON) related to rituximab or rituximab plus chemotherapy is defined as an un...
Rituximab is a monoclonal antibody directed against the CD20 antigen on normal and neoplastic B-lym...
Biomarkers of clinical response to rituximab (RTX) therapy and early predictors of outcome are still...